Newsroom | 4957 results

TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, the leader in Cellular RPM™ and the nation’s most trusted source of patient-generated vital health data, announced exceptional momentum in its integration and partnership with eClinicalWorks, one of the largest AI-powered ambulatory EHR platforms in the country. So far in 2025, the partnership has driven a 107% year-over-year increase in active Smart Meter devices used by eClinicalWorks (eCW) providers — now surpassing 25,000 active devices in the mark...

MCLEAN, Va.--(BUSINESS WIRE)--Crux, the first no-fee benefits platform working directly with pharmaceutical companies and employers of all sizes to expand transparent and affordable access to transformative FDA-approved medications, today announced Eli Lilly and Company’s Zepbound® will be the first medication available on its platform. Employers will be able to contribute non-taxed dollars to lower their employees’ out-of-pocket costs for branded therapies, starting with obesity management med...

CHICAGO & NEW YORK--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced it has received an award of up to $856,250 from Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, under its Industry Discovery and Development Partnership (IDDP) program to advance a pancreatic beta cell therapy targeting T1D using its Cellgorithm platform technology. “The daily burden for those living with t...

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), société biopharmaceutique au stade clinique développant des traitements innovants pour les maladies chroniques graves à physiopathologie métabolique, notamment metabolic dysfunction-associated steatohepatitis (MASH) et les maladies métaboliques rares (la « Société »), annonce aujourd'hui ses résultats financiers consolidés semestriels résumés pour la période close le 30 juin 2025 et fait le point sur les...

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases (the "Company"), announces today its condensed consolidated half-year financial results for the period ended June 30, 2025 and provides an update on recent events ahead of its a...

LOS ANGELES--(BUSINESS WIRE)--City of Hope® CEO Robert Stone, who leads one of the largest and most advanced cancer research and treatment organizations in the United States, has been recognized as one of the most influential leaders by two top health care trade publications: Modern Healthcare and Becker’s Hospital Review. Stone was honored for expanding access to advanced cancer care nationwide, advancing breakthrough cancer research, and developing a national network of lifesaving clinical tr...

DUBLIN--(BUSINESS WIRE)--The "Diabetic Eye Disease Devices Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering. The Diabetic Eye Disease Devices Market is currently witnessing significant growth, expanding from USD 18.92 billion in 2024 to USD 20.81 billion in 2025, and projected to reach USD 40.42 billion by 2032 at a CAGR of 9.94%. Positioned at the forefront of technological advancements and increasing clinical demands, this market offers unique opportunit...

SAN DIEGO--(BUSINESS WIRE)--SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, today announced the launch of two studies to validate its innovative GLP-1 patient stratification diagnostic platform. These studies aim to transform obesity and type 2 diabetes care by enabling healthcare providers to identify individuals most likely to benefit from GLP-1 therapies, optimizing treatment outcomes and reducing unnecessary costs....

LAS VEGAS--(BUSINESS WIRE)--Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cellbased therapies for diabetes and age-related disorders, today announced a newly published study from the Mayo Clinic reinforces the critical role of the “longevity protein” α-Klotho in vascular health and aging. The research, appearing in the Journal of the American Heart Association, demonstrates a strong association between declining α-Kloth...

MALVERN, Pa.--(BUSINESS WIRE)--LifeScan (the “Company”), a world leader in blood glucose monitoring, today announced its successful emergence from its Chapter 11 financial restructuring process following approval of its Plan of Reorganization on October 27, 2025. Through this process, the Company eliminated more than 75% of its debt, providing the financial flexibility needed to continue its leadership in the glucose management industry. In connection with emergence, LifeScan is now owned by a...